US drug prices continue to grow, on average, by double digits every year, and pressure is mounting to rein in the spending. Wells Fargo analyst David Maris issued a stark warning to biopharma investors May 2 that the US drug market is headed toward more price controls, as concern over the cost of drugs continues to mount among the American public.
"We believe the US is on a longer-term arc toward price controls and lower margins, as there is an uprising that has been percolating for years against high drug prices," Maris said in a note to investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?